on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies announces the results of the 2024 Combined General Meeting
DBV Technologies, a biopharmaceutical company, held its 2024 Combined General Meeting in Châtillon, under the chairmanship of Michel de Rosen. At this meeting, all resolutions presented by the Board of Directors were approved. This information is available on the company's website, in the section dedicated to investors. This success reflects the continued support of shareholders for the company's strategic directions, particularly in the development of treatments for food allergies and other immunological conditions.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news